Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2013

View Archived Issues

Roche to study RO-6895882 in advanced and/or metastatic solid tumors

Merck & Co. and GSK to evaluate combination regimen for renal cell carcinoma

Helsinn and Mundipharma sign agreement for fixed-dose netupitant/palonosetron

Oxford BioMedica signs option agreement with GlaxoSmithKline

Retrophin withdraws unsolicited overture to purchase Transcept Pharmaceuticals

Phase IIa data reported for the Spiegelmer olaptesed pegol in CLL and MM

Patient data show activity for NKTT-120 relevant to sickle cell vaso-occlusion

Chinese researchers present new PI3Kalpha inhibitors

New prodrugs of mGlu2/mGlu3 receptor agonists prepared at Taisho Pharmaceutical

Scientists at GenVec disclose novel vaccines for HSV

Lundbeck discovers brain-penetrant positive allosteric modulator of nAChRalpha7

Astellas Pharma and CoMentis patent new BACE1 inhibitors

Theravance divulges novel neprilysin inhibitors

U.S. group reports new antibodies for the treatment and diagnosis of cancer

Anticancer drug could be repurposed for the treatment of Parkinson's disease

Tenelia receives approval for partial change as combination therapy

Sage Therapeutics and Washington University to develop GABA-A receptor molecules

Cometriq receives positive CHMP opinion for thyroid carcinoma

Sandoz begins phase III study of biosimilar adalimumab

California Stem Cell completes phase I stem cell trial for HCC

Blaze Bioscience begins first-in-human phase I study of BLZ-100

BeiGene begins dosing in phase I BGB-283 trial

FDA approves FEIBA for prophylaxis of hemophilia A and B with inhibitors

FDA accepts Eliquis supplemental NDA for review

Sirturo approved in Russia for multidrug-resistant tuberculosis

Biogen Idec opts in to commercialization agreement for anti-TNF biosimilars in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...